An in vivo study of non-small cell lung carcinoma (NSCLC) showed that downregulation of LOXL2 accelerated disease progression and, when examining tumours from patients, higher stage disease was correlated with low LOXL2 expression [105]. Here, LOXL2 is linked to non-small cell lung carcinoma.